Medifast (NYSE:MED) Director Acquires $529,019.00 in Stock

Medifast Inc (NYSE:MED) Director Parsa Kiai bought 43,150 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was acquired at an average cost of $12.26 per share, with a total value of $529,019.00. Following the transaction, the director owned 707,492 shares of the company’s stock, valued at $8,673,851.92. This trade represents a 6.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Parsa Kiai also recently made the following trade(s):

• On Monday, August 24th, Parsa Kiai purchased 4,329 shares of Medifast stock. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $51,948.00.
• On Thursday, August 20th, Parsa Kiai acquired 43,150 shares of Medifast stock. The stock was acquired at an average cost of $11.60 per share, with a total value of $500,540.00.
• On Wednesday, August 19th, Parsa Kiai acquired 29,337 shares of Medifast stock. The shares were acquired at an average price of $11.66 per share, with a total value of $342,069.42.

Medifast Trading Up 1.2%

NYSE:MED traded up $0.15 on Friday, hitting $12.31. 77,941 shares of the company’s stock traded hands, compared to its average volume of 228,350. Medifast Inc has a 1 year low of $9.22 and a 1 year high of $14.67. The firm has a 50-day moving average price of $10.98 and a 200-day moving average price of $11.09. The company has a market cap of $137.64 million, a PE ratio of -5.28 and a beta of 0.65.

Medifast (NYSE:MED) last issued its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.37. The company had revenue of $76.38 million for the quarter, compared to the consensus estimate of $72.70 million. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. On average, research analysts forecast that Medifast Inc will post -1.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MED has been the subject of a number of research analyst reports. Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Zacks Research cut shares of Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Medifast presently has an average rating of “Reduce” and a consensus price target of $12.00.

Institutional Investors Weigh In On Medifast

Hedge funds and other institutional investors have recently made changes to their positions in the business. Chico Wealth RIA bought a new stake in shares of Medifast in the second quarter valued at approximately $223,000. Ancora Advisors LLC acquired a new stake in Medifast in the 2nd quarter worth $75,000. Empowered Funds LLC bought a new position in shares of Medifast during the 2nd quarter worth about $701,000. Bank of America Corp DE bought a new position in shares of Medifast during the 2nd quarter worth about $924,000. Finally, PDT Partners LLC acquired a new position in shares of Medifast during the second quarter valued at about $348,000. 95.51% of the stock is owned by institutional investors and hedge funds.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.